A new balloon device (the ReShape Dual Balloon) was recently approved by the FDA to treat obesity without invasive surgery.
In an effort to reduce the risk of infection spread, the FDA recently required additional label warnings about sharing of multi-dose diabetes pen devices, which are intended for single patient use only.
The FDA has requested clinical trial data on saxagliptin (Onglyza and Kombiglyze XR) to investigate a possible increase in heart failure in patients taking the drug.
The FDA has determined that the Risk Evaluation and Mitigation Strategy is no longer necessary to ensure that the benefits of rosiglitazone-containing drugs outweigh their risks.
Afrezza, a rapid-acting, inhaled human insulin, was recently approved by the FDA to treat diabetes in adults.
Dipeptidyl peptidase-4 (DPP-4) inhibitors may cause joint pain that can be severe and disabling, and some insulin pods may fail, the FDA recently warned.
The Abbott FreeStyle Insulinx blood glucose meters were recently recalled because at extremely high blood glucose levels of 1,024 mg/dL and above, the meters will display and store in memory an incorrect test result that is 1,024 mg/dL below the
New warnings will be placed on saxagliptin and alogliptin about the potential risk of heart failure, particularly in patients with heart or kidney disease, the FDA announced on April 5.
Lorcaserin hydrochloride (Belviq) was recently approved by the FDA for chronic weight management in adults.
First continuous glucose monitoring system with fully implantable glucose sensor approved | ACP Diabetes Monthly
The sensor is coated with a fluorescent chemical that produces a small amount of light when exposed to blood glucose. Every five minutes, it sends glucose measurements to a compatible device that is running a device-specific mobile app.